Cargando…

Immuno-psychiatry: an agenda for clinical practice and innovative research

BACKGROUND: The diagnostic scheme for psychiatric disorders is currently based purely on descriptive nomenclature given that biomarkers subtypes and clearly defined causal mechanisms are lacking for the vast majority of disorders. The emerging field of “immuno-psychiatry” has the potential to widen...

Descripción completa

Detalles Bibliográficos
Autores principales: Leboyer, Marion, Berk, Michael, Yolken, Robert H., Tamouza, Ryad, Kupfer, David, Groc, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084344/
https://www.ncbi.nlm.nih.gov/pubmed/27788673
http://dx.doi.org/10.1186/s12916-016-0712-5
_version_ 1782463361551695872
author Leboyer, Marion
Berk, Michael
Yolken, Robert H.
Tamouza, Ryad
Kupfer, David
Groc, Laurent
author_facet Leboyer, Marion
Berk, Michael
Yolken, Robert H.
Tamouza, Ryad
Kupfer, David
Groc, Laurent
author_sort Leboyer, Marion
collection PubMed
description BACKGROUND: The diagnostic scheme for psychiatric disorders is currently based purely on descriptive nomenclature given that biomarkers subtypes and clearly defined causal mechanisms are lacking for the vast majority of disorders. The emerging field of “immuno-psychiatry” has the potential to widen the exploration of a mechanism-based nosology, possibly leading to the discovery of more effective personalised treatment strategies. DISCUSSION: Disturbances in immuno-inflammatory and related systems have been implicated in the aetiology, pathophysiology, phenomenology and comorbidity of several psychiatric disorders, including major mood disorders and schizophrenia. A fundamental challenge in their clinical management is to identify bio-signatures that might indicate risk, state, trait, prognosis or theragnosis. Here, we provide the rationale for a clinical and research agenda to refine future clinical practice and conceptual views, and to delineate pathways toward innovative treatment discovery. CONCLUSION: The development of bio-signatures will allow clinicians to tailor interventions to the abovementioned biomarker subtypes – a major translational goal for research in this field.
format Online
Article
Text
id pubmed-5084344
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50843442016-10-28 Immuno-psychiatry: an agenda for clinical practice and innovative research Leboyer, Marion Berk, Michael Yolken, Robert H. Tamouza, Ryad Kupfer, David Groc, Laurent BMC Med Opinion BACKGROUND: The diagnostic scheme for psychiatric disorders is currently based purely on descriptive nomenclature given that biomarkers subtypes and clearly defined causal mechanisms are lacking for the vast majority of disorders. The emerging field of “immuno-psychiatry” has the potential to widen the exploration of a mechanism-based nosology, possibly leading to the discovery of more effective personalised treatment strategies. DISCUSSION: Disturbances in immuno-inflammatory and related systems have been implicated in the aetiology, pathophysiology, phenomenology and comorbidity of several psychiatric disorders, including major mood disorders and schizophrenia. A fundamental challenge in their clinical management is to identify bio-signatures that might indicate risk, state, trait, prognosis or theragnosis. Here, we provide the rationale for a clinical and research agenda to refine future clinical practice and conceptual views, and to delineate pathways toward innovative treatment discovery. CONCLUSION: The development of bio-signatures will allow clinicians to tailor interventions to the abovementioned biomarker subtypes – a major translational goal for research in this field. BioMed Central 2016-10-28 /pmc/articles/PMC5084344/ /pubmed/27788673 http://dx.doi.org/10.1186/s12916-016-0712-5 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Opinion
Leboyer, Marion
Berk, Michael
Yolken, Robert H.
Tamouza, Ryad
Kupfer, David
Groc, Laurent
Immuno-psychiatry: an agenda for clinical practice and innovative research
title Immuno-psychiatry: an agenda for clinical practice and innovative research
title_full Immuno-psychiatry: an agenda for clinical practice and innovative research
title_fullStr Immuno-psychiatry: an agenda for clinical practice and innovative research
title_full_unstemmed Immuno-psychiatry: an agenda for clinical practice and innovative research
title_short Immuno-psychiatry: an agenda for clinical practice and innovative research
title_sort immuno-psychiatry: an agenda for clinical practice and innovative research
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084344/
https://www.ncbi.nlm.nih.gov/pubmed/27788673
http://dx.doi.org/10.1186/s12916-016-0712-5
work_keys_str_mv AT leboyermarion immunopsychiatryanagendaforclinicalpracticeandinnovativeresearch
AT berkmichael immunopsychiatryanagendaforclinicalpracticeandinnovativeresearch
AT yolkenroberth immunopsychiatryanagendaforclinicalpracticeandinnovativeresearch
AT tamouzaryad immunopsychiatryanagendaforclinicalpracticeandinnovativeresearch
AT kupferdavid immunopsychiatryanagendaforclinicalpracticeandinnovativeresearch
AT groclaurent immunopsychiatryanagendaforclinicalpracticeandinnovativeresearch